| Cancer-and chemotherapy-induced anemia GM Rodgers, PS Becker, M Blinder, D Cella, A Chanan-Khan, C Cleeland, ... Journal of the National Comprehensive Cancer Network 10 (5), 628-653, 2012 | 351* | 2012 |
| Diagnosis and treatment of cancer‐related anemia JA Gilreath, DD Stenehjem, GM Rodgers American journal of hematology 89 (2), 203-212, 2014 | 264 | 2014 |
| Studying cancer-related fatigue: report of the NCCN scientific research committee JE Mortimer, AM Barsevick, CL Bennett, AM Berger, C Cleeland, ... Journal of the National Comprehensive Cancer Network 8 (12), 1331-1339, 2010 | 96 | 2010 |
| How I treat cancer-associated anemia JA Gilreath, GM Rodgers Blood, The Journal of the American Society of Hematology 136 (7), 801-813, 2020 | 65 | 2020 |
| Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma LM Alwan, K Grossmann, D Sageser, J Van Atta, N Agarwal, JA Gilreath Targeted oncology 9, 63-71, 2014 | 60 | 2014 |
| Novel approaches to treating advanced systemic mastocytosis JA Gilreath, L Tchertanov, MW Deininger Clinical pharmacology: advances and applications, 77-92, 2019 | 57 | 2019 |
| The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy GM Rodgers, JA Gilreath Acta Haematologica 142 (1), 13-20, 2019 | 54 | 2019 |
| On the safety of intravenous iron, evidence trumps conjecture M Auerbach, J Adamson, A Bircher, C Breymann, S Fishbane, ... haematologica 100 (5), e214, 2015 | 50 | 2015 |
| Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists J Gilreath, M Lo, J Bubalo Drugs 81 (11), 1285-1305, 2021 | 48 | 2021 |
| Proposed algorithm for managing ibrutinib-related atrial fibrillation A Vrontikis, J Carey, JA Gilreath, A Halwani, DM Stephens, ... Oncology 30 (11), 970-978, 2016 | 42 | 2016 |
| Intravenous iron therapy: a summary of treatment options and review of guidelines SB Silverstein, JA Gilreath, GM Rodgers Journal of Pharmacy Practice 21 (6), 431-443, 2008 | 25 | 2008 |
| Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients JA Gilreath, DS Sageser, JA Jorgenson, GM Rodgers Journal of the National Comprehensive Cancer Network 6 (6), 577-584, 2008 | 20 | 2008 |
| Total dose iron dextran infusion in cancer patients: is it SaFe2+? JA Gilreath, DD Stenehjem, GM Rodgers Journal of the National Comprehensive Cancer Network 10 (5), 669-676, 2012 | 16 | 2012 |
| Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it GM Rodgers, AL Kurtti, JA Gilreath American Journal of Hematology 94 (3), 394-395, 2019 | 12 | 2019 |
| Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: A literature summary AH Diaz, GM Rodgers, JA Gilreath Journal of Oncology Pharmacy Practice 18 (2), 264-270, 2012 | 12 | 2012 |
| Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, p lacebo‐controlled study … T Makharadze, R Boccia, A Krupa, N Blackman, DH Henry, JA Gilreath American Journal of Hematology 96 (12), 1639-1646, 2021 | 10 | 2021 |
| Eltrombopag as initial monotherapy for severe aplastic anemia—a case report GM Rodgers, JA Gilreath Annals of Hematology 97, 1517-1518, 2018 | 8 | 2018 |
| Effectiveness and safety of rivaroxaban in treatment of venous thromboembolism in cancer patients KZ Win, N Wilson, DD Stenehjem, N Tanner, GM Rodgers, J Gilreath Blood 126 (23), 2319, 2015 | 8 | 2015 |
| Comparative evaluation of the safety and effectiveness of rivaroxaban (riva) and enoxaparin (enox) for treatment of venous thromboembolism (VTE) in cancer patients. SE Hummert, J Gilreath, GM Rodgers, N Wilson, DD Stenehjem Journal of Clinical Oncology 35 (15_suppl), e18268-e18268, 2017 | 7 | 2017 |
| Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia R Pokorny, DD Stenehjem, JA Gilreath Journal of Oncology Pharmacy Practice 28 (4), 916-923, 2022 | 6 | 2022 |
